Bengaluru — Canadian drugmaker Bausch Health said on Thursday that it will spin off its eye care unit, Bausch + Lomb, into a separate, publicly listed company, seven years after acquiring it for nearly $9bn.Bausch Health, previously known as Valeant Pharmaceuticals, has sought to get past a flurry of investigations into its accounting and pricing practices under its previous management.
Since its purchase in 2013, Bausch + Lomb has been a stable source of revenue for the company, especially after the accounting issues led to a steep fall in the share price of the one-time Wall Street darling, compounded by concerns over Bausch’s large debt pile.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
Dollar totters as stocks rise amid stimulus expectationsMarkets keep a firm eye on fiscal and monetary support packages
مصدر: BDliveSA - 🏆 12. / 63 اقرأ أكثر »
This is how BP plans to transform itself into a net-zero emissions company by 2050Overall, BP has gone further than any oil company but there are areas of concern
مصدر: BDliveSA - 🏆 12. / 63 اقرأ أكثر »